Servatus Limited, an Australian biopharmaceutical company delivering leading novel autoimmune and microbiome therapies, is pleased to announce the launch of its new microbiome-based over-the-counter (OTC) biomiq skincare range.
Leading the charge in one of the most exciting new areas in skincare, biomiq utilises the skin microbiome to address the underlying causes of certain skin conditions, while helping soothe the skin and restore its natural balance.
Servatus’ proprietary clinical program investigating the role of bacteria and microbiome regulation as treatments for certain diseases enabled the Company to apply its scientific knowledge and evidence-based research to the consumer skincare market.
The first product in the biomiq skincare range to be launched is biomiq acne wipes and biomiq acne serum.
Servatus scientist Dr Rebekka Williams PhD said, “Our broader work in the Servatus labs presents a compelling opportunity to improve skin health. Acne is a cluttered, but still underserviced, market which hasn’t welcomed many novel and effective products in over four decades. As we learn more about the interaction of microbes on the skin, we believe our extensive expertise in the field of the human microbiome has supported us to develop a product that both reduces pathogenic acne forming bacteria, but at the same time, preserve and enhance the healthy ecosystem of the skin’s natural microbiome. This is a significant advancement and can allow us to make an immediate difference in skin health.”
Leading QLD Dermatologist, Dr Andrew Freeman believes there is huge potential for microbiome-based skincare.
“Our bodies contain millions of microorganisms, collectively referred to as your ‘microbiome’. Some microbes within your microbiome confer positive health benefits, others can act as pathogens. The skin microbiome is one of our body’s microbiomes, and ensuring the microbes that make it up are diverse and balanced is key to having healthy and clear skin.
“I’ve seen first-hand the significant impact acne and its effects can have on people. New offerings, targeting the microbiome, that help get acne under control and prevent future breakouts give hope to those facing the challenges of persistent mild-moderate acne.”
The new biomiq skincare range expands Servatus’ biomiq product portfolio, which already includes a range of powdered OTC TGA-listed biotherapeutics that target specific health complaints, including constipation and bloating.
In parallel, Servatus is continuing to progress its comprehensive clinical program for its live biotherapeutics. Currently four Phase 1/2 clinical trials are in progress for insomnia, IBS-C, Helicobacter Pylori and Rheumatoid Arthritis.
For more information about the biomiq skincare range, please visit biomiq.com.au
About us:
About Servatus | www.servatus.com.au
Servatus Ltd is an unlisted public biopharmaceutical company focused on creating safe, effective, and reliable microbiome-based therapeutic drugs to treat several chronic and debilitating autoimmune diseases, as well as non-antibiotic treatments for bacterial infections.
In addition to drug research and development, and ongoing clinical trials, Servatus also owns a state-of-the-art production facility. This facility means Servatus is able to oversee all aspects of the research development and production pipeline and ensure that its live microbial biotherapeutic drug candidates are made to the highest-standard and specifications, and removes the logistical uncertainty often associated with outsourcing manufacturing.
Contact details:
MEDIA
For further information please contact:
Jack McLintock
jack.mclintock@irdepartment.com.au
+61 450 608 022
